Business Wire10.07.19
Electromed Inc., a developer of airway clearance technologies, has elected two new members to its Board of Directors, John L. Erb and Gregory J. Fluet.
“We are pleased to have attracted two experienced executives from the medical device industry who will bring a wealth of relevant expertise,” said Steve Craney, board chairman. “These additions provide further strength to our board to further support Electromed’s growth opportunities.”
Erb has served as CEO and president of CHF Solutions Inc. since 2015, and as a member of its board of directors and chairman since 2012. He has also served as CEO and chairman of NeuroMedic Inc., a private company he co-founded, since 2014. Previously, Erb served as CEO from 2007 to 2018, of NuAx Inc. (formerly Cardia Access Inc.), a private medical device company involved in developing new devices for the treatment of heart disease. Erb’s prior board experience includes service as a director of SenoRx Inc., then a Nasdaq-listed company, from 2001 until its acquisition in 2010; and as chairman of the board of Vascular Solutions Inc., then a Nasdaq-listed company, until its acquisition in 2017. Erb currently serves as chairman of the board of Osprey Medical Inc. and as a director of MiroMatrix, a private biotechnology company, since 2017.
Fluet has served as a consultant with Ferring Pharmaceuticals Inc., focused on microbiome commercialization and partnering since April 2018. He served as chief business officer at Rebiotix Inc. from April 2017 until its acquisition by Ferring Pharmaceuticals in April 2018. Prior to that he started a strategic consulting practice working with various life science companies, including Rebiotix. Previously, he served as CEO at Urologix Inc., then a public company, from 2012 to January 2016. He also served as its interim chief financial officer from August 2014 to May 2015 and as its executive vice president and chief operating officer from 2008 to 2012. From 2002 to 2008, he was employed as an associate at Sapient Capital Management LLC, a healthcare focused venture capital fund.
“John and Greg each bring an extensive background in strategy development, operations and finance and their addition speaks to Electromed’s commitment to penetrate the underserved market for non-cystic fibrosis bronchiectasis with our proven SmartVest Airway Clearance System,” said Kathleen Skarvan, president and CEO. “I believe their addition to our board will benefit our entire Electromed team to accelerate our profitable revenue growth goal.”
Electromed Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System, to patients with compromised pulmonary function. The company is headquartered in New Prague, Minn., and was founded in 1992.
“We are pleased to have attracted two experienced executives from the medical device industry who will bring a wealth of relevant expertise,” said Steve Craney, board chairman. “These additions provide further strength to our board to further support Electromed’s growth opportunities.”
Erb has served as CEO and president of CHF Solutions Inc. since 2015, and as a member of its board of directors and chairman since 2012. He has also served as CEO and chairman of NeuroMedic Inc., a private company he co-founded, since 2014. Previously, Erb served as CEO from 2007 to 2018, of NuAx Inc. (formerly Cardia Access Inc.), a private medical device company involved in developing new devices for the treatment of heart disease. Erb’s prior board experience includes service as a director of SenoRx Inc., then a Nasdaq-listed company, from 2001 until its acquisition in 2010; and as chairman of the board of Vascular Solutions Inc., then a Nasdaq-listed company, until its acquisition in 2017. Erb currently serves as chairman of the board of Osprey Medical Inc. and as a director of MiroMatrix, a private biotechnology company, since 2017.
Fluet has served as a consultant with Ferring Pharmaceuticals Inc., focused on microbiome commercialization and partnering since April 2018. He served as chief business officer at Rebiotix Inc. from April 2017 until its acquisition by Ferring Pharmaceuticals in April 2018. Prior to that he started a strategic consulting practice working with various life science companies, including Rebiotix. Previously, he served as CEO at Urologix Inc., then a public company, from 2012 to January 2016. He also served as its interim chief financial officer from August 2014 to May 2015 and as its executive vice president and chief operating officer from 2008 to 2012. From 2002 to 2008, he was employed as an associate at Sapient Capital Management LLC, a healthcare focused venture capital fund.
“John and Greg each bring an extensive background in strategy development, operations and finance and their addition speaks to Electromed’s commitment to penetrate the underserved market for non-cystic fibrosis bronchiectasis with our proven SmartVest Airway Clearance System,” said Kathleen Skarvan, president and CEO. “I believe their addition to our board will benefit our entire Electromed team to accelerate our profitable revenue growth goal.”
Electromed Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System, to patients with compromised pulmonary function. The company is headquartered in New Prague, Minn., and was founded in 1992.